Updated just now · Live
Stock analysis, price data, and AI-powered insights for Ligand Pharmaceuticals Inc (LGND).
Ligand Pharmaceuticals Inc operates in the Pharmaceuticals sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for LGND.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). LGND Stock Intelligence Report. [stoxpulse.com/stocks/lgnd]
Disclaimer: The information on this page about Ligand Pharmaceuticals Inc (LGND) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Ligand Pharmaceuticals Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Citigroup Maintains Buy on Ligand Pharmaceuticals,...
6d ago
Ligand Partner Travere Therapeutics Receives Full ...
6d ago
StoxPulse AI results for LGND: Pulse Score 56/100. Primary sentiment trends from 5 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$4.62B
P/E Ratio
—
EPS
$5.68
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $282
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI in FSGS
Ligand Pharmaceuticals shares are trading higher after the company's partner Travere Therapeutics received FDA approval for a drug to treat kidney disease. Also, HC Wainwright & Co maintained its Buy rating on the stock and raised its price target from $239 to $243.
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $243
Ligand Pharmaceuticals Partner Travere Therapeutics Wins FDA Approval For First Drug Treating Rare Kidney Disease